With ADC pipeline now a top priority, Pyxis adds $152M series B
Arix joins syndicate after 12x return on ADC play VelosBio
Fresh from a strong return on its investment in VelosBio, Arix backs another antibody-drug conjugate developer.
Mar 30, 2021 | 12:01 PM GMT
Pyxis’ $152 million series B round gives the company the ability to advance